Goldman Sachs Upgrades Bristol-Myers Squibb Co. (BMY) to Conviction Buy
Tweet Send to a Friend
Get Alerts BMY Hot Sheet
Price: $46.40 +5.31%
Rating Summary:
7 Buy, 7 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Rating Summary:
7 Buy, 7 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Trade BMY Now!
Goldman Sachs upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Buy to Conviction Buy with a price target of $40.00 (from $38.00), citing the fastest growth in the sector beyond 2013.
The firm sees numerous catalysts over the next 12 months, "which should lead to increased investor confidence that BMY will be the fastest-growing drug company from 2013 until the end of the decade."
Goldman said the want to own the name "in front of the potential Eliquis launch later this year or early next, daclatasvir filing in Japan next year, and PD-1 data points in 2014."
The firm expects Bristol-Myers to grow 11% over the next five years versus 4% for its peers. This is in addition to the 4.1% dividend yield.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $33.14 yesterday, with a 52 week range of $28.70-$36.34.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm sees numerous catalysts over the next 12 months, "which should lead to increased investor confidence that BMY will be the fastest-growing drug company from 2013 until the end of the decade."
Goldman said the want to own the name "in front of the potential Eliquis launch later this year or early next, daclatasvir filing in Japan next year, and PD-1 data points in 2014."
The firm expects Bristol-Myers to grow 11% over the next five years versus 4% for its peers. This is in addition to the 4.1% dividend yield.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $33.14 yesterday, with a 52 week range of $28.70-$36.34.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Barclays Upgrades Terex (TEX) to Overweight
- Benchmark Boosts PT on R.R. Donnelley (RRD)
Create E-mail Alert Related Categories
Analyst PT Change, Hot Upgrades, UpgradesRelated Entities
Goldman Sachs Conviction Buy List, Goldman Sachs, Dividend
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
